Home » Newsletters » BioWorld Science

BioWorld Science

May 8, 2006

View Archived Issues

Genentech recaps Q1 highlights

Quarterly activities at Gilead Sciences

No statistical significance for intranasal ketamine in postoperative pain study

Avigen's glial inhibitor reverses neuropathic pain symptoms

Genzyme and Brookwood team up to offer drug delivery solutions

Preclinical data presented on bicifadine in models of neuropathic pain

Epidural NGX-424 relieves postoperative pain in vivo

PPARgamma agonists a novel strategy for neuropathic pain

Protox begins phase I study of PRX-302 in localized recurrent prostate cancer

NicOx studies 24-hour blood pressure profile of HCT-3012

Completion of phase II study of leuprolide acetate in male Alzheimer's patients

BioAlliance Pharma establishes new sales and marketing subsidiary

AEterna Zentaris and U. of Montreal collaborate on ghrelin research

New phase III study to evaluate Telcyta with Doxil in ovarian cancer

Molecular Pharmacology reports on new topical COX-2 inhibitor MPL-356

Hollis-Eden plans phase I for Neumune in hospital-acquired infections

Solvay and Innogenetics renew research collaboration for further three years

AstraZeneca discontinues development of Galida

Phase IIb studies of bremelanotide in erectile dysfunction complete enrollment

ImmunoGen and Genentech sign new TAP agreements

Protalex completes phase I study of PRTX-100

MAA submission for prolonged-release paliperidone for schizophrenia

European approval for Valtropin

Recent patents disclose novel therapeutic agents for gastrointestinal disorders

Recent patents report new treatments for psychological disorders

Novel therapeutic agents imparted for inflammatory disorders

The marine product misakinolide A could be useful in glaucoma therapy

Geranylgeranyltransferase type I, a potential therapeutic target in glaucoma

Snapshots on novel therapeutic strategies for choroidal neovascularization

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...